Furthermore, we found CUL4B could also significantly enhanced the sensitivity of mouse subcutaneous tumors to trametinib and dabrafenib treatment, resulting in tumor growth retardation (Fig. 6J). This evidence concerns the gene CUL4B and neoplasm.